The poor dissolution characteristic of water insoluble drugs is a major challenge for formulation scientists. About 50% of orally administered drugs suffer from formulation difficulties related to their water insolubility. Thus it is rate limiting step for achieving optimum bioavailability of such drugs by pharmaceutical industry with developments of new pharmaceutical products.There are various methods but liquisolid technique is a new and promising method that can change the dissolution rate of water insoluble drugs. According to the new formulation method of liquisolid compacts, liquid medications such as solutions or suspensions of water insoluble drugs in suitable nonvolatile liquid vehicles can be converted into acceptably flowing and compressible powders by blending with selected powder excipients. In this case, even though the drug is in a solid dosage form, it is held within the powder substrate in solution or, in a solubilized, almost molecularly dispersed state, which contributes to the enhanced drug dissolution and release properties. Liquisolid system is characterized by flow behavior, wettability, powder bed hydrophilicity, saturation solubility, drug content, differential scanning calorimetry, Fourier transform infra red spectroscopy, powder X-ray diffraction, scanning electron microscopy, in-vitro release and in-vivo evaluation.
Introduction
Oral route is the most desirable and preferred method of administering therapeutic agents for their systemic effects. In addition the oral route medication is generally considered as the first avenue investigated in the discovery and development of new chemical entities and pharmaceutical formulations mainly because of *Corresponding Author:
asmapathan9@gmail.com patient acceptance, convenience in administration and cost effective manufacturing process. For many drug substances, conventional immediate release formulation provide clinically effective therapy while maintaining the required balance of pharmacokinetic and pharmacodynamic profile with an acceptable level of safety to the patient. Thus one of the major challenges to drug development today is poor solubility, as an estimated 40% of all newly developed drugs are poorly soluble or insoluble in water 1 .
About 50% of orally administered drugs suffer from formulation difficulties related to their water insolubility. As a result, much research has been conducted into methods of improving drug solubility and dissolution rates to increase the oral absorption of hydrophobic drugs. One way of improving dissolution involves the reduction of particle size and/or increasing saturation solubility 2 . One of the most common approaches used to reduce particle size is milling, a mechanical micronization process. Milling is a well established technique which is relatively cheap, fast and easy to scale-up. However, milling has several disadvantages, the main one being the limited opportunity to control important characteristics of the final particle such as size, shape, morphology, surface properties and electrostatic charge. In addition, milling is a high energy process which causes disruptions in the drug"s crystal lattice, resulting in the formulation of disordered or amorphous regions in the final product 3 . An alternative to milling involves the size enlargement of drug particle with different polymers and excipients, for example compaction, melt granulation and liquisolid technique. The compaction of drug with hydroxypropyl methylcellulose (HPMC) and other hydrophilic polymers shows change in crystal form and habit may change the solubility, dissolution rate and other physicochemical properties. These are the easily scalable methods to combine poorly water-soluble drugs and dissolution rate enhancing polymers without the use of solvent or heat addition 4, 5 . 
Drugs that can be incorporated into liquisolid systems

Development of Dosage Forms with Poorly Water Soluble Drugs
The increased emergence of poorly water soluble active compounds presents specific obstacles for the development of both immediate release and modified release dosage forms. Poorly water soluble drugs will be inherently released at a slow rate owing to their limited solubility within the GI contents. The challenge for poorly water soluble drugs is to enhance the rate of dissolution. This in turn subsequently improves absorption and bioavailability 6 .
Formulation methods targeted at dissolution enhancement of poorly soluble substances are continuously introduced 7, 8 .
Various methods used to increase the solubility of poorly water soluble drugs which are given below.
Micronization
The particle size reduction technique enhance the solubility and dissolution rate of poorly water soluble drugs due to the enormous surface that is generated.
Solvent Deposition
In this method, the poorly aqueous soluble drug such as nifedipine is dissolved in an organic solvent like alcohol and deposited on a inert, hydrophilic, solid matrix such as starch or microcrystalline cellulose evaporation of solvent.
Use of soluble Prodrug
Here the physico-chemical properties of the drug are improved by bioreversible chemical alteration. The most common prodrug strategy involves the incorporation of polar or ionizable moiety into the parent compound to improve aqueous solubility 9 . 
Solid dispersion
Need of Liquisolid System
The oral route remains the preferred route of drug administration due to its convenience, good patient compliance and low medicine production costs. In order for a drug to be absorbed into the systemic circulation following oral administration, the drug must be dissolved in the gastric fluids. Thus, one of the major challenges to drug development today is poor solubility, as an estimated 40% of all newly developed drugs are poorly soluble or insoluble in water 13 . In addition, up to 50% of orally administered drug compounds suffer from formulation problems related to their low solubility and high lipophilicity 14,15,16 .
Bioavailability of poorly water soluble hydrophobic drugs (class II in biopharmaceutics classification system) is limited by their solubility and dissolution rate. The dissolution rate of these drugs can be improved by decreasing particle size, decreasing crystallinity, and/or increasing the surface area. Several studies have been carried out to increase the dissolution rate of drugs by decreasing the particle size, by creating nanoparticles and microparticles. However, the fine drug particles have high tendency to agglomerate due to van der Waals attraction or hydrophobicity, which both result in a decrease in surface area over time. Another way of increasing the dissolution rate is adsorption of the drug onto a high-surface area carrier. In this technique, the drug is dissolved in an organic solvent followed by soaking of the solution by a highsurface-area carrier such as silica. Here, agglomeration of the drug particles is prevented due to the binding of drug to the carrier. However, due to the presence of the residual solvent in the drug formulation, it is disadvantageous to use toxic solvents 17, 18, 19 . To overcome the problem, the technique of "liquisolid compacts" is a new and promising approach towards dissolution enhancement. Liquisolid compacts possess acceptable flowability and compressibility properties. They are prepared by simple blending with selected powder excipients referred to as the carriers and the coating materials. Many grades of cellulose, starch, lactose, etc. can be used as carriers, whereas silicas of very fine particle size can be used as coating materials. In such systems, the drug existed in a molecular state of subdivision and systems were free flowing, onadherent, dry looking powders 20, 21 . This technique was successfully applied for low dose water-insoluble drugs. Due to significantly increased wetting properties and surface area of drug available for dissolution, liquisolid compacts of water insoluble substances may be expected to display enhanced drug release characteristics and, consequently, improved oral bioavailability. Since dissolution of a nonpolar drug is often the rate limiting step in gastrointestinal absorption, better bioavailability of an orally administered water-insoluble drug is achieved when the drug is already in solution, thereby displaying enhanced dissolution rates. The technique of liquisolid compacts has been successfully employed to improve the in vitro release of poorly water soluble drugs such as Carbamazepine, Famotidine, Piroxicam, Indomethacin, Hydrocortisone, Naproxen and Prednisolone.
Advantages of Liquisolid Systems
A great number of slightly and very slightly water-soluble and practically water-insoluble liquid and solid drugs, such as those previously mentioned, can be formulated into liquisolid systems using the new formulationmathematical model. It is well established that better availability of an orally administered water-insoluble drug is achieved when the drug is in solution form. In liquisolid compacts, even though the drug is in a tabletted or encapsulated dosage form, it is held in a solubilized liquid state, which consequently contributes to increased drug wetting properties, thereby enhancing drug dissolution. Another advantage of liquisolid systems is that their production cost is lower than that of soft gelatin capsules because the production of liquisolid systems is similar to that of conventional tablets. Still another possible advantage of liquisolid systems, particularly for powdered liquid drugs, should be mentioned. During dissolution of a liquisolid tablet, after the disintegration process is completed, the drug solution or liquid drug, carried on the suspended and thoroughly agitated primary particles, is dispersed throughout the volume of the dissolution medium; such a phenomenon does not extensively occur during the dissolution process of soft gelatin capsule preparations. Therefore, since more drug surface is exposed to the dissolving medium, liquisolid systems exhibit enhanced drug release. Most liquid or solid water-insoluble drugs may be formulated into immediate-release or sustained-release"liquisolid compacts" or "liquisolid microsystems 22 
Disadvantages
Formulation of high dose lipophilic drugs the liquisolid tablet is one of the limitations of this technique. In order to achieve acceptable flowability and compactability for liquisolid powder formulation, high levels of carrier material and coating materials should be added. This will increase the weight of tablets to above one gram which makes them difficult to swallow.
Consequently, it is impossible with conventional tablet methods to convert high dose to liquisolid tablets with a tablet weight of less than 50mg. Dissolution profile enhancement occurs in the presence of low levels of hydrophilic carrier, where coating material is not significant. 41 .
Principle of Liquisolid Compacts
Determination of angle of slide
Angle of slide is used as a measure of the flow properties of powders. Determination of angle of slide is done by weighing the required amount of carrier material and placed at one end of a metal plate with a polished surface. The end is gradually raised till the plate becomes angular to the horizontal at which powder is about to slide. This angle is known as angle of slide. Angle of 33º is regarded as optimum 42 .
Determination of flowable liquid retention potential (Φ value)
The term "flowable liquid-retential potential" (Φ-value) of a powder material describes its ability to retain a specific amount of liquid while maintaining good flow properties. The Φ-value is defined as the maximum weight of liquid that can be retained per unit weight of the powder material in order to produce an acceptably flowing liquid/powder admixture. 
Evaluation of Liquisolid Systems Flow behaviour
The flowability of a powder is of critical importance in the production of pharmaceutical dosage forms in order to reduce high dose variations. Angle of repose, Carr"s index and Hausner"s ratio were used in order to ensure the flow properties of the liquisolid systems. Pre compression studies of the prepared liquisolid Powder systems In order to ensure the suitability of the selected excipients, Fourier Transform Infra Red Spectroscopy, Differential scanning Calorimetry, Xray Diffraction and Scanning Electron Microscope studies are to be performed. In addition, flowability studies are also to be carried out to select the optimal formulae for compression, prior to the compression of the powders the dosage forms such as into tablets and capsules.
Dissolution studies
In-Vitro release profiles of drug from the preferred tablets were studied using dissolution apparatus and compared with the formulated Liquisolid tablet. Drug release, % drug dissolved can be calculated of both the formulation results are estimated.
Differential scanning calorimetry (DSC)
This is prerequisite to know if any possible interaction present between the excipients and the drug used in the formulation. The characteristic peak in the DSC thermogram belongs to drug is absent that indicates that the drug is present in moleculary dispersed in this system 43 .
X-ray diffraction (XRD)
To get justification that the drug is in the solubilised state or converted into amorphous form because of disappearance of characteristic peaks belongs to drug and their by appearance of peaks which belongs to carrier is absorbed 44 .
Scanning electron microscopy (SEM)
This study confirms that there are any crystals present, or else drug is present in the solubilised form by absence of crystals of drug 45 .
Stability studies
Drug content was determined after the crystals were charged for accelerated stability studies according to ICH guidelines. Samples were taken and analysed for specified intervals.
Liquisolid Tablets
The 
